AstraZeneca AZN and Bristol-Myers
Squibb Company BMY today announced results from a two-week
Phase IIa pilot study evaluating dapagliflozin added to insulin in 70
adult patients with sub-optimally controlled type 1 diabetes. Results
from this study showed that in patients treated with dapagliflozin, no
subjects discontinued due to lack of glycemic control, few genital and
urinary tract infections were reported and hypoglycemia was observed in
all treatment groups. In addition, mean daily blood glucose derived from
7-point glucose measurements trended downward in all treatment groups
through day seven and reductions in total daily insulin dosing at day
seven were observed with dapagliflozin. These findings will be presented
Sunday, June 23, in a late-breaking poster session at the 73rd
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in